HYDERABAD: Dr Reddy’s Laboratories Ltd has introduced Montelukast Sodium Oral Granules in the US market recently, after the approval of United States Food & Drug Administration (USFDA). It is a bioequivalent generic version of Singulair (Montelukast Sodium) oral granules.
The brand as per the records of IMS Health, Singulair Oral Granules reported about $61 million for last one year, ending July, in the US. The 4 mg Montelukast Sodium Oral Granules are accessible in unit measured quantity of 30.
The company is a well known global pharmaceutical corporation which is dedicated in providing reasonable and inventive medicines for healthier lives with three core businesses such as Global Generics and Proprietary Products, Pharmaceutical Services and Active Ingredients. The organization’s main motive is lowering healthcare costs and improving access to medicines for unmet medicinal requirements.